U.S. Markets closed
  • S&P 500

    4,128.80
    +31.63 (+0.77%)
     
  • Dow 30

    33,800.60
    +297.03 (+0.89%)
     
  • Nasdaq

    13,900.19
    +211.39 (+1.54%)
     
  • Russell 2000

    2,243.47
    +20.42 (+0.92%)
     
  • Crude Oil

    59.34
    -0.26 (-0.44%)
     
  • Gold

    1,744.10
    -14.10 (-0.80%)
     
  • Silver

    25.33
    -0.26 (-1.02%)
     
  • EUR/USD

    1.1905
    +0.0031 (+0.2619%)
     
  • 10-Yr Bond

    1.6660
    +0.0340 (+2.08%)
     
  • Vix

    16.69
    -0.47 (-2.74%)
     
  • GBP/USD

    1.3706
    -0.0032 (-0.2316%)
     
  • USD/JPY

    109.6500
    -0.1800 (-0.1639%)
     
  • BTC-USD

    59,309.31
    +854.19 (+1.46%)
     
  • CMC Crypto 200

    1,235.89
    +45.20 (+3.80%)
     
  • FTSE 100

    6,915.75
    +30.43 (+0.44%)
     
  • Nikkei 225

    29,768.06
    +37.26 (+0.13%)
     

Recap: Alcon Q4 Earnings

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Alcon (NYSE:ALC) were flat in after-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share decreased 8.89% over the past year to $0.41, which were in line with the estimate of $0.41.

Revenue of $1,925,000,000 higher by 2.34% year over year, which beat the estimate of $1,890,000,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

View more earnings on ALC

Revenue guidance hasn't been issued by the company for now.

Technicals

52-week high: $76.26

Company's 52-week low was at $39.37

Price action over last quarter: Up 10.91%

Company Profile

Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun-off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with 41% of revenue in the U.S. market, and the firm has a strong presence in the European Union and Japan.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.